Image3_DNA methylation-mediated FGFR1 silencing enhances NF-κB signaling: implications for asthma pathogenesis.TIF by Minglu Meng (19725085)

“…Furthermore, treatment with 5-Aza-CdR, a DNA demethylating agent, markedly increased the expression of FGFR1 mRNA in BEAS-2B, PCS-301-011, and HBEpiC cells. …”

Image2_DNA methylation-mediated FGFR1 silencing enhances NF-κB signaling: implications for asthma pathogenesis.TIF by Minglu Meng (19725085)

“…Furthermore, treatment with 5-Aza-CdR, a DNA demethylating agent, markedly increased the expression of FGFR1 mRNA in BEAS-2B, PCS-301-011, and HBEpiC cells. …”

Image1_DNA methylation-mediated FGFR1 silencing enhances NF-κB signaling: implications for asthma pathogenesis.TIF by Minglu Meng (19725085)

“…Furthermore, treatment with 5-Aza-CdR, a DNA demethylating agent, markedly increased the expression of FGFR1 mRNA in BEAS-2B, PCS-301-011, and HBEpiC cells. …”

Diminished ADAMTS and reduced versican cleavage in <i>Galnt1</i> nulls. by E Tian (685836)

“…(D) Confocal images of intact versican (versican, green), (E) cleaved versican (DPEAAE; green), and nuclei (Nu; blue) show an increase in intact versican accompanied by a decrease in cleaved versican in E12.5 OFT cushions and E14.5 AoV of <i>Galnt1^-/-</i> relative to wild type. …”

DataSheet1_Retinal Inflammation, Oxidative Stress, and Vascular Impairment Is Ablated in Diabetic Mice Receiving XMD8-92 Treatment.PDF by Scott J. Howell (3343367)

Table_8_Omega 3 supplementation reduces C-reactive protein, prostaglandin E2 and the granulocyte/lymphocyte ratio in heavy smokers: An open-label randomized crossover trial.DOCX by Ingrid Elisia (3214848)

“…Objectives<p>Given the current controversy concerning the efficacy of omega 3 supplements at reducing inflammation, we evaluated the safety and efficacy of omega 3 on reducing inflammation in people with a 6-year lung cancer risk >1.5% and a C reactive protein (CRP) level >2 mg/L in a phase IIa cross-over study.…”

Presentation_1_Omega 3 supplementation reduces C-reactive protein, prostaglandin E2 and the granulocyte/lymphocyte ratio in heavy smokers: An open-label randomized crossover trial.... by Ingrid Elisia (3214848)

“…Objectives<p>Given the current controversy concerning the efficacy of omega 3 supplements at reducing inflammation, we evaluated the safety and efficacy of omega 3 on reducing inflammation in people with a 6-year lung cancer risk >1.5% and a C reactive protein (CRP) level >2 mg/L in a phase IIa cross-over study.…”

Table_4_Omega 3 supplementation reduces C-reactive protein, prostaglandin E2 and the granulocyte/lymphocyte ratio in heavy smokers: An open-label randomized crossover trial.DOCX by Ingrid Elisia (3214848)

“…Objectives<p>Given the current controversy concerning the efficacy of omega 3 supplements at reducing inflammation, we evaluated the safety and efficacy of omega 3 on reducing inflammation in people with a 6-year lung cancer risk >1.5% and a C reactive protein (CRP) level >2 mg/L in a phase IIa cross-over study.…”

Table_6_Omega 3 supplementation reduces C-reactive protein, prostaglandin E2 and the granulocyte/lymphocyte ratio in heavy smokers: An open-label randomized crossover trial.DOCX by Ingrid Elisia (3214848)

“…Objectives<p>Given the current controversy concerning the efficacy of omega 3 supplements at reducing inflammation, we evaluated the safety and efficacy of omega 3 on reducing inflammation in people with a 6-year lung cancer risk >1.5% and a C reactive protein (CRP) level >2 mg/L in a phase IIa cross-over study.…”

Table_9_Omega 3 supplementation reduces C-reactive protein, prostaglandin E2 and the granulocyte/lymphocyte ratio in heavy smokers: An open-label randomized crossover trial.DOCX by Ingrid Elisia (3214848)

“…Objectives<p>Given the current controversy concerning the efficacy of omega 3 supplements at reducing inflammation, we evaluated the safety and efficacy of omega 3 on reducing inflammation in people with a 6-year lung cancer risk >1.5% and a C reactive protein (CRP) level >2 mg/L in a phase IIa cross-over study.…”

Table_2_Omega 3 supplementation reduces C-reactive protein, prostaglandin E2 and the granulocyte/lymphocyte ratio in heavy smokers: An open-label randomized crossover trial.DOCX by Ingrid Elisia (3214848)

“…Objectives<p>Given the current controversy concerning the efficacy of omega 3 supplements at reducing inflammation, we evaluated the safety and efficacy of omega 3 on reducing inflammation in people with a 6-year lung cancer risk >1.5% and a C reactive protein (CRP) level >2 mg/L in a phase IIa cross-over study.…”

Table_7_Omega 3 supplementation reduces C-reactive protein, prostaglandin E2 and the granulocyte/lymphocyte ratio in heavy smokers: An open-label randomized crossover trial.DOCX by Ingrid Elisia (3214848)

“…Objectives<p>Given the current controversy concerning the efficacy of omega 3 supplements at reducing inflammation, we evaluated the safety and efficacy of omega 3 on reducing inflammation in people with a 6-year lung cancer risk >1.5% and a C reactive protein (CRP) level >2 mg/L in a phase IIa cross-over study.…”

Table_1_Omega 3 supplementation reduces C-reactive protein, prostaglandin E2 and the granulocyte/lymphocyte ratio in heavy smokers: An open-label randomized crossover trial.DOC by Ingrid Elisia (3214848)

“…Objectives<p>Given the current controversy concerning the efficacy of omega 3 supplements at reducing inflammation, we evaluated the safety and efficacy of omega 3 on reducing inflammation in people with a 6-year lung cancer risk >1.5% and a C reactive protein (CRP) level >2 mg/L in a phase IIa cross-over study.…”

Table_3_Omega 3 supplementation reduces C-reactive protein, prostaglandin E2 and the granulocyte/lymphocyte ratio in heavy smokers: An open-label randomized crossover trial.DOC by Ingrid Elisia (3214848)

“…Objectives<p>Given the current controversy concerning the efficacy of omega 3 supplements at reducing inflammation, we evaluated the safety and efficacy of omega 3 on reducing inflammation in people with a 6-year lung cancer risk >1.5% and a C reactive protein (CRP) level >2 mg/L in a phase IIa cross-over study.…”

Cellular senescence is increased in MSCs obtained from old rats. by Cao Ma (3710134)

Fits of the mathematical model to data involving adoptive transfer of different numbers of GP33-specific effector (panels A&C) or memory (panels B&D) CD8 T cells. by Vitaly V. Ganusov (142019)

Redox correlation in muscle lengthening and immune response in eccentric exercise by Feng He (47348)

“…Interestingly, the combination of ascorbic acid (vitamin C) and α-tocopherol (vitamin E) supplementation attenuated the decrease in B-cell lymphoma 2 (Bcl-2) at 24 hours following acute downhill running. …”

FTI-277 treatment reversed burn-induced attenuated insulin-stimulated phosphorylation of Akt and GSK-3β, and glucose uptake in skeletal muscle. by Harumasa Nakazawa (684211)

“…Insulin-stimulated phosphorylation of Akt at threonine 308 and serine 473 was blunted at 3 days after burn compared with sham-burn, which was reversed by FTI-277 treatment (C-F). Likewise, insulin-stimulated phosphorylation of GSK-3β at serine 9 was decreased in burned mice, which was reversed by FTI-277 treatment (H, I). n = 5 mice per group for saline-injected mice, n = 6 mice per group for insulin-injected sham-burned mice, n = 8 mice per group for insulin-injected burned mice. …”

FTI-277 treatment reversed burn-induced impaired insulin receptor (IR)-insulin receptor substrate-1 (IRS-1) signaling in skeletal muscle. by Harumasa Nakazawa (684211)

“…Insulin-stimulated IR phosphorylation was attenuated at 3 days after burn compared with sham-burned mice, which was almost completely restored by FTI-277 treatment (C, D). Burn decreased IRS-1 protein expression (E) and insulin-stimulated IRS-1 phosphorylation (F, G), both of which were reversed by FTI-277. …”

Azilsartan Improves Salt Sensitivity by Modulating the Proximal Tubular Na⁺-H⁺ Exchanger-3 in Mice by Masaki Hatanaka (410349)

“…Two weeks later, the azilsartan group showed significantly lower blood pressure during the light period than the candesartan and vehicle groups (azilsartan: 103.1 ± 1.0; candesartan: 111.7 ± 2.7; vehicle: 125.5 ± 2.5 mmHg; <i>P</i> < 0.05; azilsartan or candesartan <i>vs</i>. vehicle). …”